Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders.
about
Bipolar disorder and mechanisms of action of mood stabilizersAmino acid substitutions in the pore helix of GluR6 control inhibition by membrane fatty acidsRNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndromeStructural basis for recruitment of tandem hotdog domains in acyl-CoA thioesterase 7 and its role in inflammationCeramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ AccumulationRole of platelets in neuroinflammation: a wide-angle perspectiveA secretory phospholipase A2-mediated neuroprotection and anti-apoptosis.Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease.Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study.BLOC-1 deficiency causes alterations in amino acid profile and in phospholipid and adenosine metabolism in the postnatal mouse hippocampus.Extracellular-derived calcium does not initiate in vivo neurotransmission involving docosahexaenoic acid.Purification and characterization of a cytosolic Ca(2+)-independent phospholipase A(2) from bovine brain.Acid-sensing ion channels (ASICs): therapeutic targets for neurological diseases and their regulationCytosolic phospholipase A2 and lysophospholipids in tumor angiogenesisUpregulated expression of brain enzymatic markers of arachidonic and docosahexaenoic acid metabolism in a rat model of the metabolic syndromeOral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in ratsDietary n-6 PUFA deprivation downregulates arachidonate but upregulates docosahexaenoate metabolizing enzymes in rat brain.Alcohol-induced interactive phosphorylation of Src and toll-like receptor regulates the secretion of inflammatory mediators by human astrocytes.Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for ω-3 fatty acids.Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.Synthesis and effects of conjugated tocopherol analogues on peptide nucleic acid hybridisation.Kainic Acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines.Myelin abnormalities in the optic and sciatic nerves in mice with GM1-gangliosidosisSevere alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease.Persistent Nociception Triggered by Nerve Growth Factor (NGF) Is Mediated by TRPV1 and Oxidative Mechanisms.Dietary n-6 polyunsaturated fatty acid deprivation increases docosahexaenoic acid metabolism in rat brain.Effect of fish oil supplement in maintenance hemodialysis patients: a systematic review and meta-analysis of published randomized controlled trials.Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila.D-Alanylation of Teichoic Acids and Loss of Poly-N-Acetyl Glucosamine in Staphylococcus aureus during Exponential Growth Phase Enhance IL-12 Production in Murine Dendritic Cells.Calcium-independent phospholipases A2 and their roles in biological processes and diseases.Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway.Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC, Elevated Intracellular Calcium, and Modulation of Synapsin 1 Dynamics and Phosphorylation.Redox processes in neurodegenerative disease involving reactive oxygen speciesMechanism-based inhibition of iPLA2β demonstrates a highly reactive cysteine residue (C651) that interacts with the active site: mass spectrometric elucidation of the mechanisms underlying inhibitionRole of Lipids in Brain Injury and Diseases.The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids.Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3
P2860
Q22252332-597D40B3-6F49-4C0C-9180-4D6183597199Q24648841-0C6B31EC-2642-47A0-8188-CAB67E7372CBQ26992035-9B0A9EFB-530C-4EAD-9F2B-C2C413331A9CQ27645619-8E51242F-B802-4646-A25A-0BAD42645237Q28087030-767E9484-30BA-4C1C-85D4-F5A22F8EA6D0Q28393808-70430EF9-DEAC-4C24-A358-7262121E408FQ33506180-3B6F5A08-1BA9-409A-8014-47CE308B14D5Q33518442-432FAFD0-6E7A-4EFE-9AAA-2C41E3C1F791Q33565825-A03F1CD0-82FE-4DD7-A1F4-7D25C8BADF0BQ33803741-F6F788AC-FFF2-4A98-A202-3899901CBA9BQ33824051-16F619A6-ED58-4F55-A365-0D2A773F2C3AQ33899339-CEDFCCF5-BA45-4B99-A01C-9FBA5E3596F3Q33993276-0E10BD37-6BE0-4C43-93C3-E50CA7F63378Q34004751-00C89CC8-AA33-47DC-8F7D-5D6B788AD064Q34049519-03CCDF20-D1E6-4B09-B3E9-871CC5908B1CQ34145860-DF4E2E8B-AF09-4A9B-BEF3-1A092C7D6033Q34461400-9DF290FF-7877-4EBC-938B-046CF5BC35BBQ34476283-733E262F-8740-4160-9428-4CC04A9073BBQ34478836-2314B7B2-18DA-424D-BEEB-064F9F244F2EQ34498210-B747D34F-96AB-4E71-91C1-A2CC34739B72Q34660464-6675A134-44F5-4CE7-B918-6983D2A66328Q34785252-FBCF968D-20BA-462A-9527-8FFBE8D60DC0Q34874275-FFB29704-A630-49AF-98D8-E7CA55640074Q34977314-1D9265C1-D79C-482B-8F89-3FFE33F32634Q35092168-BF220D17-CE8E-4349-A0C4-2BB19F203358Q35126311-9D8F7E61-512F-4278-A854-CCCC580E4280Q35287117-F2E636E6-BB9C-47A5-BB72-2067C6C3A632Q35675208-6A5796C2-86CF-4C0D-9C6C-4FF98204448BQ35812881-22C4A9E8-CDD0-4755-81BC-A50377656704Q35838579-058CE9A1-65B7-4ECC-9ABB-BBBB84566BF2Q35860358-CC0CDFB4-8478-46B1-B4E8-77E4BC55C214Q35922364-15F12338-2A65-4B86-BED1-82710A8C3973Q35994344-DD8804C6-C327-41AB-985D-5A42DFCE8ACBQ36234872-DC1847E1-6F54-450D-BA37-E8DE5140C456Q36441996-EA0ECD9D-ACE6-4F83-BB96-85EAA282B161Q36460613-7B7EF076-EB2A-4AF4-9D29-3C880BCB92D0Q37027268-5DD63AC0-C430-4CE0-8662-0307058C21E5Q37051065-48FFB4E8-83FA-4CDA-8C30-19A3F3DDC46CQ37077987-AE2EAE5A-494B-4CF6-A98E-2AF50029009FQ37152021-8A7FFCB5-5451-4C72-9ABF-57D7DF88C4A9
P2860
Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@ast
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@en
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@nl
type
label
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@ast
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@en
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@nl
prefLabel
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@ast
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@en
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@nl
P2093
P356
P1476
Inhibitors of brain phospholip ...... tment of neurologic disorders.
@en
P2093
Akhlaq A Farooqui
Lloyd A Horrocks
Wei-Yi Ong
P304
P356
10.1124/PR.58.3.7
P577
2006-09-01T00:00:00Z